Unigene Laboratories Inc., of Boonton, N.J., said the FDA scheduled an advisory committee meeting March 5 to discuss whether the benefit of calcitonin salmon for the treatment of postmenopausal osteoporosis outweighs a potential risk of cancer
MorphoSys AG, of Martinsried, Germany, said it completed the sale of research and diagnostic antibody division AbD Serotec to Bio-Rad Laboratories Inc., of Hercules, Calif., for about $70 million in cash
Auxilium Pharmaceuticals Inc., of Malvern, Pa., and Xstelos Holdings Inc., of New York, said they received notice that Upsher-Smith Laboratories Inc., of San Diego, filed a 505(b)(2) new drug application containing a Paragraph IV certification for testosterone gel, referring to 10 U.S
Forest Laboratories Inc., of New York, said it entered a settlement agreement with Mumbai, India-based Glenmark Pharmaceuticals Ltd., and its affiliates, related to patent infringement litigation brought by Forest in response to Glenmark's abbreviated new drug application (ANDA) seeking to market generic versions of Forest's Bystolic (nebivolol) tablets
Unigene Laboratories Inc., of Boonton, N.J., retained Canaccord Genuity to help explore strategic options that may include the partnering of its technology, out-licensing of intellectual property, divestiture of assets and possible sale of the company or one of its business units
Forest Laboratories Inc., of New York, and Gedeon Richter plc, of Budapest, Hungary, said Forest submitted a new drug application for cariprazine, a dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors, for use in schizophrenia and bipolar mania
Ranbaxy Laboratories Inc., of Gurgaon, India, launched Absorica (isotretinoin) capsules for severe, recalcitrant, nodular acne in patients younger than 12
BioWorld International | Wednesday, November 28, 2012
Unigene Laboratories Inc., of Boonton, N.J., and Tarix Pharmaceuticals Ltd., of Cambridge, Mass., agreed to develop oral TXA127, Tarix's lead peptide drug candidate
Ranbaxy Laboratories Inc., of Gurgaon, India, launched Absorica (isotretinoin) capsules for severe, recalcitrant, nodular acne in patients younger than 12
Forest Laboratories Inc., of New York, and Adamas Pharmaceuticals Inc., of Emeryville, Calif., partnered to develop a fixed-dose combination (FDC) of Namenda XR (memantine HCl extended release), which is FDA-approved for Alzheimer's, and donepezil HCl for dementia of Alzheimer's in the U.S. The two companies will collaborate on development of the product, with Forest owning exclusive U.S
IGI Laboratories Inc., of Buena, N.J., will launch its first generic products later in 2012, after being appointed the authorized generic distributor for certain products of Medimetriks Pharmaceuticals Inc
Columbia Laboratories Inc., of Livingston, N.J., confirmed that the FDA denied partner Parsippany, N.J.-based Watson Pharmaceuticals Inc.'s formal dispute resolution request (FDRR) related to the new drug application (NDA) for Prochieve (progesterone gel 8 percent) for the prevention of preterm birth in women with a short cervical length
Columbia Laboratories Inc., of Livingston, N.J., said it received a letter from Nasdaq indicating it no longer meets the $1 minimum bid price requirement for continued listing
Discovery Laboratories Inc., of Warrington, Pa., provided a commercial update for Surfaxin (lucinactant) to prevent respiratory distress syndrome in infants and Afectair, an aerosol delivery device
Forest Laboratories Inc., of New York, said it inked a deal with moksha8, of Sao Paolo, Brazil, providing Forest with a commercial footprint in Latin America and giving moksha8 access to antidepressant drug Viibryd (vilazodone) and potentially other Forest products for the Latin American market
Tarsa is developing an oral calcitonin product under a licensing deal with Unigene Laboratories Inc., of Boonton, N.J., for the treatment and prevention of postmenopausal osteoporosis
Forest Laboratories Inc., of New York, and Pierre Fabre Laboratories, of Castres, France, said Forest submitted a new drug application for levomilnacipran, a serotonin norephinephrine reuptake inhibitor, for the treatment of major depressive disorder in adults
Unigene Laboratories Inc., of Boonton, N.J., said the FDA scheduled an advisory committee meeting March 5 to discuss whether the benefit of calcitonin salmon for the treatment of postmenopausal osteoporosis outweighs a potential risk of cancer